(Q51490010)

5 April 2018

title

Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants. (English)

1 reference

5 April 2018

1 reference

Mossman SP

1

1 reference

5 April 2018

Evans LS

2

1 reference

5 April 2018

Fang H

3

1 reference

5 April 2018

Staas J

4

1 reference

5 April 2018

Tice T

5

1 reference

5 April 2018

Raychaudhuri S

6

1 reference

5 April 2018

Grabstein KH

7

1 reference

5 April 2018

Cheever MA

8

1 reference

5 April 2018

Johnson ME

9

1 reference

5 April 2018

language of work or name

English

0 references

publication date

1 May 2005

1 reference

5 April 2018

published in

Vaccine

1 reference

5 April 2018

volume

23

1 reference

5 April 2018

issue

27

1 reference

5 April 2018

page(s)

3545-3554

1 reference

5 April 2018

Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

DNA vaccination against neu reduces breast cancer incidence and metastasis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Biodegradable microparticles as a delivery system for measles virus cytotoxic T cell epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Effective adjuvants for the induction of antigen-specific delayed-type hypersensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Biodegradable microspheres as a vaccine delivery system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation: particle size study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Particle size studies for subcutaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Immunological aspects of controlled antigen delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Clinical pharmacokinetic studies of a human haemopoietic growth factor, GM-CSF

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Characterization of poly(glycolide-co-D,L-lactide)/poly(D,L-lactide) microspheres for controlled release of GM-CSF

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Monophosphoryl lipid A (MPL) upregulates major histocompatibility complex (MHC) class I expression by increasing interferon-gamma (IFN-gamma)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

Helping the CD8(+) T-cell response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

A Comparison of the Immunomodulating Properties of Two Forms of Monophosphory1 Lipid A Analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.149

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.01.149

1 reference

5 April 2018

1 reference

5 April 2018